Acton-based diabetes equipment manufacturer Insulet has reorganized its executive structure amid a 21% gain in first-quarter revenue. Jim Hollingshead will continue to lead the company as president and CEO.
“Our new organizational design creates a more focused and specialized structure that strengthens our commercial capabilities and fosters further innovation and cross-functional collaboration,” Hollingshead said in a Thursday press release.
Insulet will implement the new organizational structure on July 1.
Eric Benjamin will serve as the chief product and customer experience officer, a newly created role. Prior to joining the company in 2015, Benjamin performed various roles at Abbott Laboratories of Chicago.
Mark Field will fill the newly created role of chief technology officer. Prior to joining Insulet in 2019, Field served as chief technology officer at Thermo Fisher Scientific of Waltham.
The role of chief commercial officer was split into two general manager positions. Patrick Crannell will continue as international general manager, and the company is searching for a U.S. general manager.
Executive Vice President and Chief Commercial Officer Bret Christensen will leave the company on Friday to pursue other opportunities, but will provide consulting services during the transition, according to the press release. Christensen joined the board of Newton-based women’s health company Axena Health in February, according to his LinkedIn page.
The reorganization was announced on the same day as the company announced that first-quarter revenue was $358.1 million, compared to $295.4 million in the first quarter of 2022.
Insulet produces a tubeless, wearable insulin pump called Omnipod and accompanying technology for patients with type 1 diabetes who are unable to produce sufficient insulin in their own bodies. The company’s Omnipod 5 Automated Insulin Delivery System integrates a constant glucose monitor, eliminating the need for patients to stick their fingers to test their blood glucose levels. The company also tailors its platform to deliver non-insulin drugs subcutaneously.
